M&A Deal Summary

Actelion Acquires CoTherix

On November 20, 2006, Actelion acquired life science company CoTherix for 420M USD

Acquisition Highlights
  • This is Actelion’s 1st transaction in the Life Science sector.
  • This is Actelion’s largest (disclosed) transaction.
  • This is Actelion’s 1st transaction in the United States.
  • This is Actelion’s 1st transaction in California.

M&A Deal Summary
Date 2006-11-20
Target CoTherix
Sector Life Science
Buyer(s) Actelion
Deal Type Add-on Acquisition
Deal Value 420M USD

Target

CoTherix

South San Francisco, California, United States
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the potential treatment of cardiovascular disease. CoTherix, Inc. licensed the exclusive U.S. rights to Ventavis® from Schering AG, which currently markets Ventavis® in Europe and Australia. In June 2006, CoTherix, Inc., licensed exclusive rights to develop and commercialize oral and inhaled formulations of Fasudil, a rho-kinase inhibitor, for the treatment of PAH and stable angina in North America and Europe from Asahi Kasei Pharma Corporation.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Actelion

Allschwil, Switzerland
Category Company
Founded 1997
Sector Life Science
Employees2,500
DESCRIPTION

Actelion Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Actelion was formed in 1997 and has its corporate headquarters in Allschwil, Switzerland.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (California) 1 of 1
Country (United States) 1 of 2
Year (2006) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-31 Ceptaris Therapeutics

Malvern, Pennsylvania, United States

Ceptaris Therapeutics Inc. is a specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL. If approved, Ceptaris' investigational drug would be the first FDA-approved topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Buy $250M
Mergr

Product

Company

Legal